Adam Ball, who lives with cystic fibrosis which affects his ability to breathe, will swim the length of 13 lakes in the Lake ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO ® (ivacaftor ...

BB Biotech reported a net loss of CHF 241 mn for Q1 2025. The share price closed the quarter at a 14.1% discount to NAV, broadly in line with year-end 2024. The share price performance for the quarter ...

Driven by the continued performance of TRIKAFTA/KAFTRIO, product revenue rose 16% year-over-year to $2.9 billion, surpassing the estimate of $2.8 billion. Meanwhile, the company's bottom-line also ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

The company also secured a positive CHMP opinion for KAFTRIO®, broadening its cystic fibrosis franchise to younger patient populations in Europe. Alnylam obtained expanded FDA approval for ...

It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF ...